2Davis SR. An overview of the antifungal properties of allicin and its breakdown products-the possibility of a safe and effective antifungal prophylactic [J]. Mycoses, 2005,48(2):95.
7Thomas JC, Madigan M. A retrospective study to evaluate a computer based model for amplifying early anti-fungal intervention and microbial detection of patients at risk for fungemia. San Antonio, TX: Seventh Annual Focus on Fungal Infections, 1997.
8Uzun O, Ascioglu S, Anaissie EJ, et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32(12)∶1713-1717.
9Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33(2)∶177-186.
10Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89(7)∶1611-1625.
